checkAd
    Startseite > Aktien > Atea Pharmaceuticals > Nachrichten
    Atea Pharmaceuticals Aktie
    3,6700
     
    USD
    +1,66 %
    +0,0600 USD
    Letzter Kurs 01.06.24 Nasdaq
    3,6600
     
    USD
    5.700 STK
    Geldkurs 31.05.24
    3,6700
     
    USD
    200 STK
    Briefkurs 31.05.24
    ISIN: US04683R1068 · WKN: A2QGE7 · SYM: AVIR · USA

    Neueste Nachrichten

    Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
    29.05.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
    22.05.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
    14.05.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
    07.05.24 · globenewswire · Atea Pharmaceuticals
    Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
    29.04.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
    27.03.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    28.02.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
    21.02.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
    08.01.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    03.01.24 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
    13.11.23 · globenewswire · Atea Pharmaceuticals
    Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
    08.11.23 · globenewswire · Atea Pharmaceuticals